Literature DB >> 29018268

Biological activity of intervenolin analogs with a phenyl substituent.

Hikaru Abe1, Manabu Kawada1,2, Masayuki Igarashi1, Shun-Ichi Ohba2, Chigusa Hayashi1, Chiharu Sakashita1, Takumi Watanabe1, Masakatsu Shibasaki1.   

Abstract

Intervenolin analogs with a phenyl substituent at the 2- or 3-position were synthesized. The compounds (3-11) showed weak or no inhibitory activity toward the growth of MKN-74 gastric adenocarcinoma cells, even in the presence or absence of the corresponding Hs738 stromal cells, whereas 2-substituted analogs exhibited selective anti-Helicobacter pylori activity. Introduction of a pendant side chain on the nitrogen alleviated their acute toxicity in mice. The 2-phenyl-substituted analogs are reasonable structural templates for structure-activity relationship studies toward the development of anti-H. pylori agents that do not affect human cells.The Journal of Antibiotics advance online publication, 11 October 2017; doi:10.1038/ja.2017.123.

Entities:  

Year:  2017        PMID: 29018268     DOI: 10.1038/ja.2017.123

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  10 in total

Review 1.  Stromal effects on mammary gland development and breast cancer.

Authors:  Bryony S Wiseman; Zena Werb
Journal:  Science       Date:  2002-05-10       Impact factor: 47.728

Review 2.  The multiple roles of tumour stroma.

Authors:  N Wernert
Journal:  Virchows Arch       Date:  1997-06       Impact factor: 4.064

3.  New quinolone compounds from Pseudonocardia sp. with selective and potent anti-Helicobacter pylori activity: taxonomy of producing strain, fermentation, isolation, structural elucidation and biological activities.

Authors:  K A Dekker; T Inagaki; T D Gootz; L H Huang; Y Kojima; W E Kohlbrenner; Y Matsunaga; P R McGuirk; E Nomura; T Sakakibara; S Sakemi; Y Suzuki; Y Yamauchi; N Kojima
Journal:  J Antibiot (Tokyo)       Date:  1998-02       Impact factor: 2.649

4.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.

Authors:  Jennifer A Tuxhorn; Gustavo E Ayala; Megan J Smith; Vincent C Smith; Truong D Dang; David R Rowley
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

5.  Fibroblast-mediated acceleration of human epithelial tumor growth in vivo.

Authors:  J L Camps; S M Chang; T C Hsu; M R Freeman; S J Hong; H E Zhau; A C von Eschenbach; L W Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

6.  A microplate assay for selective measurement of growth of epithelial tumor cells in direct coculture with stromal cells.

Authors:  Manabu Kawada; Yuya Yoshimoto; Kazuhisa Minamiguchi; Hiroyuki Kumagai; Tetsuya Someno; Tohru Masuda; Masaaki Ishizuka; Daishiro Ikeda
Journal:  Anticancer Res       Date:  2004 May-Jun       Impact factor: 2.480

7.  Synthesis of intervenolin, an antitumor natural quinolone with unusual substituents.

Authors:  Hikaru Abe; Manabu Kawada; Hiroyuki Inoue; Shun-ichi Ohba; Akio Nomoto; Takumi Watanabe; Masakatsu Shibasaki
Journal:  Org Lett       Date:  2013-04-17       Impact factor: 6.005

8.  Fibroblast-dependent tumorigenicity of cells in nude mice: implication for implantation of metastases.

Authors:  O Picard; Y Rolland; M F Poupon
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

9.  Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2.

Authors:  Manabu Kawada; Hiroyuki Inoue; Shun-Ichi Ohba; Masaki Hatano; Masahide Amemiya; Chigusa Hayashi; Ihomi Usami; Hikaru Abe; Takumi Watanabe; Naoko Kinoshita; Masayuki Igarashi; Tohru Masuda; Daishiro Ikeda; Akio Nomoto
Journal:  J Antibiot (Tokyo)       Date:  2013-05-01       Impact factor: 2.649

10.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression.

Authors:  Rosa F Hwang; Todd Moore; Thiruvengadam Arumugam; Vijaya Ramachandran; Keith D Amos; Armando Rivera; Baoan Ji; Douglas B Evans; Craig D Logsdon
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.